Amgen Faces Regulatory Challenges but Dividend Appears Secure
Amgen is dealing with regulatory issues involving the FDA and Colorado regulators, yet its financial resilience suggests minimal impact on dividend sustainability. Enbrel's revenue has declined due to Medicare price-setting under the Inflation Reduction Act.
Tickers: $AMGN
Topics: Amgen dividend sustainability Enbrel FDA price caps Tavneos